4-Chlor-1H-pyrrolo<2,3-d>pyridazin | 23200-60-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Chlor-1H-pyrrolo<2,3-d>pyridazin
• 英文别名: 4-chloro-1H-pyrrolo[2,3-d]pyridazine；4-Chloro-1H-pyrrolo[2,3-d]pyridazine
• CAS: 23200-60-4
• 化学式: C₆H₄ClN₃
• 分子量: 153.571
• InChiKey: VSSKAVWLIZKBSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  吗啉 、 4-Chlor-1H-pyrrolo<2,3-d>pyridazin 以 乙二醇甲醚 为溶剂， 反应 4.0h， 生成 4-(N-Morpholino)-(1H)-pyrrolo<2,3-d>pyridazin
  参考文献：
  名称：

  Marquet,J.-P. et al., Chimica Therapeutica, 1968, vol. 3, p. 348 - 355

  摘要：

  DOI：

文献信息

• Diazaindole-dicarbonyl-piperazinyl antiviral agents
  申请人：Bender A. John

  公开号：US20050124623A1

  公开（公告）日：2005-06-09

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of — may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  这项发明包括通式I的替代二氮杂吲哚-二羰基-哌嗪基衍生物，其中：Q选自由一组，可以表示成键；T为—C(O)—或—CH(CN)—；以及—Y—选自由一组，包括其组成物及其用于治疗HIV感染的用途。
• [EN] OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021123297A1

  公开（公告）日：2021-06-24

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GlcNAc水解酶（OGA）抑制剂。本发明还涉及包含这种化合物的制药组合物，制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗OGA抑制有益的疾病，例如tau病理学，特别是阿尔茨海默病或进行性核上性麻痹症；伴随tau病理学的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或alpha突触蛋白病，特别是帕金森病，帕金森病引起的痴呆（或帕金森病引起的神经认知障碍），带有Lewy小体的痴呆，多系统萎缩症或Gaucher病引起的alpha突触蛋白病。
• DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS
  申请人：Bender John A.

  公开号：US20080125439A1

  公开（公告）日：2008-05-29

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of -- may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.

  该发明涉及一种一般式I的取代的二氮杂吲哌唑-二羧酰基-哌嗪基衍生物，其中：Q选自由以下组成的群：-可能代表键；T为-C（O）-或-CH（CN）-；和-Y-选自由以下组成的群：其组成物及其用于治疗HIV感染的用途。
• US7902204B2
  申请人：——

  公开号：US7902204B2

  公开（公告）日：2011-03-08
• [EN] DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DIAZAINDOLE-DICARBONYLE-PIPERAZINYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005054247A1

  公开（公告）日：2005-06-16

  The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula (I) wherein: Q is selected from the group consisting of Formulas (II), (III) and (IV) may represent a bond; T is -C(O)- or -CH(CN)-; and -Y- is selected from the group consisting of Formulas (V) and (VI) compositions thereof and their use for treating HIV infection.